HCV NS5A Replication Complex Inhibitors. Part 4.1 Optimization for Genotype 1a Replicon Inhibitory Activity
Denis R. St. Laurent(Bristol-Myers Squibb (United States)), Lawrence B. Snyder(Arvinas (United States)), Bradley C. Pearce(Bristol-Myers Squibb (Germany)), Ying-Kai Wang(Bristol-Myers Squibb (United States)), Mengping Liu(China University of Geosciences (Beijing)), Makonen Belema, Rudolph G. Krause(Bristol-Myers Squibb (United States)), Jason T. Goodrich(Bristol-Myers Squibb (United States)), Nicholas A. Meanwell(Mario Negri Institute for Pharmacological Research), Donald R. O’Boyle(Bristol-Myers Squibb (United States)), Lourdes Valera(Bristol-Myers Squibb (United States)), Xuejie Yang(Chinese Academy of Sciences), Omar D. Lopez(Bristol-Myers Squibb (United States)), Peter T. Nower, Jin-Hua Sun(University of Science and Technology of China), J. Romine(Bristol-Myers Squibb (United States)), Michael H. Serrano‐Wu(Broad Institute), Min Gao(Central South University), Hua Fang(Shanghai Jiao Tong University), Fukang Yang(Bristol-Myers Squibb (United States)), Min Ding(Jiangsu University), Van N. Nguyen, Julie A. Lemm(Bristol-Myers Squibb (United States))
Cited by 35
Related Papers
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
|Nature|2010|940
Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
|Nature Communications|2020|432
Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity
|Nature Immunology|2021|422
Inhibition of Activator Protein-1, NF-κB, and MAPKs and Induction of Phase 2 Detoxifying Enzyme Activity by Chlorogenic Acid
|Journal of Biological Chemistry|2005|388
IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases
|Nature Biotechnology|2024|258